About
Cantargia AB is a biopharmaceutical company from Sweden that specializes in the development of antibody therapies for the treatment of cancer. The company was founded in 2009 and is based in Lund, Sweden. Cantargia has a unique business model that is based on the discovery of new therapeutic antibodies and the use of these antibodies in cancer treatment. The company works closely with leading research institutions and cancer centers to integrate the latest scientific findings into the development of new cancer drugs. Cantargia specializes in two main areas: antibody development and cancer drug development. The company has an extensive pipeline of products in various stages of clinical development, including an innovative therapeutic for the treatment of pancreatic cancer. One of Cantargia's key products is CAN04, an antibody targeted against a protein called IL1RAP. IL1RAP is expressed on the surface of many different cancer cells and is a promising target for cancer treatment. CAN04 has shown efficacy against a variety of cancer types in preclinical studies. The company also has other products in its pipeline targeting pancreatic, breast, blood, prostate, liver, lung, and ovarian cancer. The company is also working on the development of therapeutic antibodies for the treatment of autoimmune diseases. Cantargia has established strong partnerships with leading pharmaceutical and biotech companies to successfully develop and market its pipeline of products. The company has strategic partnerships with companies such as BioInvent and Precision for Medicine to support its clinical studies and product commercialization. Cantargia has a strong team of experienced leaders and scientists who are driving the company's success. The company's employees are highly qualified and dedicated, working hard to develop new innovative cancer treatments. Overall, Cantargia has shown impressive growth in recent years and has established itself as a key player in the biotech industry. The company has an innovative business model and an extensive pipeline of promising products targeting the treatment of cancer and other major diseases. With strong partnerships and an experienced team, Cantargia is well positioned to continue expanding and bringing groundbreaking new therapies to the market.
Annual results
Reported figures, SEK
| Year | Revenue | Net income | Net margin | Free cash flow |
|---|---|---|---|---|
| 2025 | 316M | 146M | 46.2% | — |
| 2024 | — | -161M | — | — |
| 2023 | — | -280M | — | — |
| 2022 | — | -371M | — | — |
| 2021 | — | -366M | — | — |
CANTA.ST in MarketPulse
The live chart with RSI and moving averages, the price, news, signals and price alerts for Cantargia AB are inside MarketPulse — currently in private beta.
Company data by Eulerpool. Logos provided by Elbstream. Reported figures, not investment advice.